The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 339:705 September 3, 1998 Number 10
NextNext

Hepatitis A Vaccination

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: Werzberger et al. (April 16 issue)1 report that on the basis of six years of follow-up after the Monroe efficacy trial, vaccination against hepatitis A is protective. However, it still remains to be determined how long the vaccine will be effective. We know that the level of antibody after immunization with either one of the commercially available vaccines is much lower than the level associated with natural infection. Standard assays with a lower limit of detection of 100 mIU per milliliter usually fail to detect vaccine-induced levels of hepatitis A virus antibody. Once there has been exposure . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.